US Patent

US9993467 — Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione

Formulation · Assigned to Celgene Corp · Expires 2030-05-19 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of the drug 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, which is a compound related to POMALIDOMIDE.

USPTO Abstract

Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.

Drugs covered by this patent

chembl-chembl43452 (POMALIDOMIDE)

Patent Metadata

Patent number: US9993467
Jurisdiction: US
Classification: Formulation
Expires: 2030-05-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.